Skip to Main Content
Try STAT+ TODAY
Trending:
Health
First Opinion
Biotech
STAT+
The Readout

One way to goose your stock price, PhRMA gets existential, & a CRISPR debate

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Feb. 17, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for February 17, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Lured by a bigger payday, a medical device maker…
Lured by a bigger payday, a medical device maker sold fake plastic parts. Many were implanted…
Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
How Biogen got Aduhelm approved, Sanofi’s future in mRNA,…
How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga

Recommended Stories